Konstantina Stankovic, M.D., Ph.D., FACS

Associate Professor of Otolaryngology, Harvard Medical School


Otology and Neurotology

Board Certification

  • Otolaryngology-Head and Neck Surgery
  • Neurotology

Main Campus
243 Charles Street
Boston, MA 02114
Phone: 617-573-3972
Fax: 617-573-3637
Tues. 8:30 a.m. - 5 p.m.



Dr. Stankovic is a board-certified ear and skull base surgeon and a Ph.D.-trained auditory neuroscientist. Her medical education includes a medical degree from Harvard Medical School (magna cum laude), an internship in general surgery at Massachusetts General Hospital, a residency in otolaryngology—head and neck surgery at Mass. Eye and Ear/Harvard Medical School, and a fellowship in neurotology—skull base surgery at Mass. Eye and Ear/Harvard Medical School.

Her scientific training includes bachelor degrees in physics and in biology from Massachusetts Institute of Technology (MIT), a Ph.D. degree in auditory neuroscience from MIT, and post-doctoral training in molecular neuroscience at Harvard Medical School and Boston Children's Hospital.

She has received numerous awards, including the Association of MIT Alumnae award for academic excellence, the Henry Asbury Christian Award for outstanding performance in research and scholarly activities at Harvard Medical School, the Burt Evans young investigator award from the National Organization for Hearing Research, the Thomas A. McMahon Mentoring Award from Harvard-MIT Division of Health Science and Technology, and the Benjamins Prize from the Collegium Oto-Rhino-Laryngologicum Amictiae Sacrum. The American Academy of Otolaryngology—Head and Neck Surgery honored her by Howard House, MD Lectureship for Advances in Otology in 2015. She serves on the editorial board of Otology and Neurotology. She is a fellow of the American Neurotology Society, a fellow of the American College of Surgeons, and past president of the American Auditory Society.

Concurrent with her clinical activities, she directs a basic science laboratory that focuses on hearing and hearing restoration. The approach is interdisciplinary, combining tools of systems neuroscience with optics, ultra-low power electronics, molecular biology, and genomics to improve diagnostics, prognostics, and therapeutics for deafness. Recent research highlights include optical imaging of cells inside the inner ear without contrast dyes, development of a prototype chip for a fully implantable cochlear implant, energy extraction from the inner ear to run electronics, and discovery that salicylates may prevent growth of intracranial tumors (vestibular schwannomas/ acoustic neuromas) which cause hearing loss. Her research has been published in leading journals and has also received international media coverage, including by National Public Radio, ABS news, CBS news, Wall Street Journal, Los Angeles Times, Canadian Broadcasting Corporation, Danish Broadcasting Corporation, and New England Cable News.

Her clinical and research work drives and reinforces one another. Her involvement in cutting-edge research gives her patients the opportunity to participate in clinical trials that could lead to breakthroughs in addressing the problems of participating patients, while advancing the knowledge frontier of the auditory field.

Clinical Interests

Otology/neurotology, including hearing loss in adults and children, cochlear implants and other implantable hearing devices, acoustic neuromas (vestibular schwannomas), otosclerosis, cholesteatoma, and tumors of temporal bone.

Research Interests

Degeneration and regeneration of the inner ear, development of novel diagnostic and prognostic tools for hearing loss, mechanisms of sensorineural hearing loss due to acoustic neuromas (vestibular schwannomas), otosclerosis, and noise trauma.

Visit Dr. Stankovic's Research Page and Laboratory Page.

Select Publications

Human audiometric thresholds do not predict specific cellular damage in the inner ear. Landegger LD, Psaltis D, Stankovic KM. Hear Res. 2016;335:83-93.

Activation of TRAIL-DR5 pathway promotes sensorineural degeneration in the inner ear. Kao SY, Soares VY, Kristiansen AG, Stankovic KM. Aging Cell. 2016;15(2):301-8.

Secreted Factors from Human Vestibular Schwannomas Can Cause Cochlear Damage. Dilwali S, Landegger LD, Soares VY, Deschler DG, Stankovic KM. Sci Rep. 2015; 5:18599.

Revealing Hearing Loss: A Survey of How People Verbally Disclose Their Hearing Loss. West JS, Low JC, Stankovic KM. Ear Hear. 2016;37(2):194-205.

A Fully-Implantable Cochlear Implant SoC with Piezoelectric Middle-Ear Sensor and Arbitrary Waveform Neural Stimulation. Yip M, Jin R, Nakajima HH, Stankovic KM, Chandrakasan AP. IEEE J Solid-State Circuits. 2015;50(1):214-229.

Transactivation of human osteoprotegerin promoter by GATA-3. Kao SY, Stankovic KM. Sci Rep. 2015;5:12479.

Immediate and delayed cochlear neuropathy after noise exposure in pubescent mice. Jensen JB, Lysaght AC, Liberman MC, Qvortrup K, Stankovic KM. PLoS One. 2015;10(5):e0125160.

Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit human vestibular schwannoma growth. Dilwali S, Briët MC, Kao SY, Fujita T, Landegger LD, Platt MP, Stankovic KM. Mol Oncol. 2015;9(7):1359-70.

Nonsteroidal anti-inflammatory medications are cytostatic against human vestibular schwannomas. Dilwali S, Kao SY, Fujita T, Landegger LD, Stankovic KM. Transl Res. 2015;166(1):1-11. 

A complete list of research publications can be seen at www.pubmed.gov.



  • Harvard Medical School and Harvard/MIT Division of Health Sciences and Technology, M.D.
  • MIT and Harvard/MIT Division of Health Sciences and Technology, Ph.D.


  • Massachusetts General Hospital (General Surgery)


  • Harvard Medical School (Otolaryngology)


  • Massachusetts Eye and Ear Infirmary (Neurotology and Skull Base Surgery)